Five cases of candidal meningitis in human immunodeficiency virus (HIV) -infected patients have been diagnosed in our hospital. This article describes these cases and reviews another nine previously reported in the literature. Most patients (71%) had at least one well-known predisposing factor for candidiasis. Median CD4 cell count was 135/mm 3 . Headache and fever, in the absence of focal neurologic signs, were the predominant clinical features. The CSF analysis revealed mild pleocytosis and hypoglycorrachia, indistinguishable from those seen in tuberculous or cryptococcal meningitis. Twelve patients (92%) received amphotericin B for a median of 51 days, in combination with flucytosine in five cases. The overall mortality among treated patients was 31%. Although the risk of relapse of candidal meningitis is unknown, maintenance antifungal therapy was given to seven patients (63%), usually with fluconazole. Candida species must be kept in mind as a cause of chronic meningitis in HIV-infected patients who have a known predisposing factor.
Candidal infection of the CNS is an uncommon manifestation
Hospital diagnosed from January 1990 through April 1996. We noted risk factors for HIV infection, predisposing factors for of disseminated infection due to Candida species. It usually occurs in immunosuppressed patients [1] , in patients treated with broadinvasive candidiasis, clinical course, laboratory findings, treatment and outcome. spectrum antibiotics, in association with intravenous hyperalimentation, following surgical manipulation of a mucosal site colonized
Criteria for the diagnosis of candidal meningitis were: (1) isolation of Candida species in CSF culture or histopathologic with Candida species, or following a neurosurgical procedure [2, 3] . It has also been described as a complication of intravenous evidence of candidiasis in meningeal tissue and (2) clinical and CSF findings suggestive of meningitis, in addition to the drug abuse [4] . Clinicopathologic forms of candidal CNS infection include diffuse cerebritis with microabscesses, parenchymal abpresence of systemic candidiasis, diagnosed by isolation of the yeast from an extracranial site; clinical and CSF improvescesses, vasculitis, and meningitis [5] .
Although candidiasis is the most frequent fungal infection in ment due to antifungal therapy; and exclusion of other pathogens. We defined as chronic meningitis the presence of symppatients with HIV infection or AIDS [6] , in most cases it involves only the foregut (mouth, pharynx, and esophagus). CNS candidiatoms suggestive of meningitis for at least 1 month before diagnosis [9] . sis seems to be an exceptional complication of HIV infection: Levy et al. [7] reported 5 cases among 366 neurologically symp-A review of the published reports of candidal meningitis in HIV-infected adults was performed. MEDLINE was searched tomatic HIV-infected patients, including 4 with brain abscesses and 1 child with AIDS and probable candidal meningoencephalifor the years 1983 -1996 and included articles in all languages. This review was supplemented by examination of major texttis. Furthermore, in an autopsy series of 121 HIV-infected patients with CNS involvement, Koppel et al. [8] reported only one case books and follow-up of additional references quoted in the articles located. For the purpose of this review, cases with of multiple candidal brain abscesses.
This study presents five cases of candidal meningitis in HIVevidence of parenchymal abscesses were excluded. infected adults and reviews those previously reported in the literature, in order to characterize the clinical features and outResults come of candidal meningitis in this population.
Patients. From January 1990 to October 1996, five cases Patients and Methods of candidal meningitis among HIV-infected patients were identified at our institution, which represented 0.11% of all HIVWe reviewed retrospectively the medical records of all HIVinfected individuals seen during that period. The median CD4 cell count, among the eight patients for whom nosed -despite the fact that CSF cultures were negativebecause extracranial candidiasis was proved by isolation of C. this determination was available at the time of admission, was 135/mm 3 (range, 25 -312/mm 3 ). albicans from a costochondral node, by response to antifungal therapy, and by exclusion of other pathogens. Only five patients (36%) had had a prior AIDS-related opportunistic disease at the time of diagnosis. Eight patients had One patient's candidal meningitis was diagnosed at autopsy. CSF cultures for bacteria, mycobacteria and other fungi, and previous episodes of mucosal candidiasis. A history of at least one predisposing factor for systemic or CNS candidiasis was latex agglutination cryptococcal antigen were negative. In the five cases diagnosed at our institution, CSF abnormalities pernoted in 10 of the cases (71%): active intravenous drug addiction in 9 (64%) and a ventriculoperitoneal shunt (in place at the sisted despite clinical improvement. Three patients' CSF parameters completely normalized after a median of 6 months. onset of meningitis) in 1. The most frequent Candida species involved was Candida albicans (13 cases, including our 5 paTherapy and outcome. One patient died before diagnosis and specific antifungal treatment (diagnosis was made at autients), while Candida tropicalis was isolated in only 1 case.
Clinical presentation. Headache (13 cases; 93%) and fever topsy). Of the 13 patients treated, 12 (92%) received amphotericin B, and 6 received it in combination with oral flucytosine. (12 cases; 86%) were the most frequent symptoms, with a mean duration of 58 days before admission (range, 12 -365 One patient received both intrathecal and intravenous amphotericin B. The total dose of amphotericin B ranged from 786 days). Nuchal rigidity was observed in seven patients (50%). Four patients had altered mental status, usually disorientation to 2,500 mg. Two patients received treatment with fluconazole: one was switched to treatment with intravenous amphotericin or confusion, but focal neurological signs were rare: two patients each presented with a third-nerve palsy and diplopia, B because of poor response, whereas the other refused amphotericin B therapy and then received oral fluconazole (resulting respectively. Cerebral CT scanning showed meningeal enhancement in 1 patient and hydrocephalus in 3 (21%); the in adequate evolution). Seven patients (50%) were initially thought to have tubercuremaining 10 patients (71%) had atrophy or a normal CT. MRI was performed on 5 patients, showing meningeal enhancement lous meningitis and received specific therapy for a mean of 22 days (range, 7 -40 days). There were four deaths among treated in 2 of them, 1 of whom presented with vasculitis and a frontal granuloma not observed on CT.
patients; the overall mortality due to candidal meningitis was 31%. Of these four patients who died despite treatment, only CSF findings. CSF pleocytosis (õ500 cells/mm 3 ) was noted in all cases. The CSF WBC counts ranged from 7 to two lived long enough to receive a course of antifungal therapy similar in length to that of the survivors. One patient's death, 346/mm 3 , with a median of 78/mm 3 before treatment, and with a polymorphonuclear cell predominance in eight patients 4 months after diagnosis, was due to cerebral infarction attributed to candidal meningitis. (57%). The CSF glucose level was õ40 mg/dL in 11 patients (78%), and the median CSF protein level was 83 mg/dL (range, Median duration of follow-up was 395 days (range, 15 -1,395 days). Maintenance therapy, given to 7 patients for a 23 -580 mg/dL). Of the eight patients for whom adenosine deaminase activity was determined, two (25%) presented with median of 110 days (range, 30 -1,325 days), was with fluconazole in 5 cases, ketoconazole in 2, and weekly amphotericin B a value of ú10 IU/L.
Microbiological studies. Blood cultures were negative for in 1. During follow-up, one patient had a relapse of candidal meningitis 55 days after the interruption of maintenance therall patients. The diagnosis was initially made by gram staining of CSF for 28.5% of patients (four cases). A Candida species apy with fluconazole, but it abated with a new course of combined treatment. Another patient not receiving secondary prowas recovered from the CSF of 11 patients (79%) after a median time of 6 days (range, 1 -40 days) and usually after rephylaxis had a relapse of candidal meningitis 150 days after the first episode. peated spinal taps. Candida species. Despite the frequency of coinfection in AIDS the cellular defect is related to T lymphocytes more than to patients, the lack of another diagnosis and the response to neutrophils and macrophage function. Not surprisingly, 71%
antifungal treatment suggested the diagnosis of candidal meninof patients in this review had a known predisposing factor gitis. Cryptococcal meningitis was unlikely in these patients for candidal meningitis, which might have contributed to the because both had a high CD4 cell count, a situation in which acquisition of CNS candidal infection. All but two cases have cryptococcosis is very uncommon [27] . These two cases show been reported from Spain, suggesting a higher incidence of this that deep-tissue candidiasis may be associated with CNS infeccomplication in a determined geographic area.
tion and that therefore the isolation of Candida species organHowever, the predominant risk factor for HIV infection in isms from any site in the body bespeaks potential CNS involveSpain is intravenous drug abuse, and systemic candidiasis in ment. addicts who use brown heroin in fresh lemon juice has been
The most appropriate treatment for candidal meningitis has described [20] . This fact, along with the relatively low incinot been established. Smego et al.
[28] recommended combined dence of candidal meningitis in our HIV-infected patients with therapy with amphotericin B and flucytosine, because this comvariable levels of immunodepression, suggests that the associabination is associated with rates of survival of 88%. However, tion of spontaneous candidal meningitis and HIV infection, in the optimal cumulative dose of amphotericin B is unknown, the absence of predisposing factors to candidiasis, is possible and several cases were managed before fluconazole was availbut uncommon.
able. In spite of its high activity against most strains of Candida Although direct inoculation following lumbar puncture or and its excellent CSF penetration, the role of fluconazole has after ventriculoperitoneal shunt placement has been described not been subjected to controlled evaluation in humans.
[21], the exact pathogenesis of candidal meningitis remains
In our series, one patient was cured with fluconazole therapy, unknown. The likely route of infection in cases of disseminated while another had to be switched to treatment with intravenous candidiasis is hematogenous spread from a variety of peripheral amphotericin B. In animal studies, higher efficacy in terms of sites of active candidal infection, as it has been described in meningeal sterilization was found with use of amphotericin B previous studies in non-HIV-infected patients, who present than with fluconazole [29] . The failure of fluconazole treatment with CNS involvement in 48% -71% of cases [22, 23] .
in a child with candidal meningitis, attributed to the high MIC, Although blood cultures were negative, we believe that this has also been reported, although he had a ventriculoperitoneal was the cause of meningeal involvement in most of our patients shunt that was not removed [30] . and that it was related to the high frequency of intravenous Intrinsic resistance of C. albicans to fluconazole in vivo is drug addiction. Accidental inoculation of Candida species from unusual, unless the isolate is derived from a patient receiving the skin during the diagnostic lumbar punctures is not likely long-term suppressive therapy with this agent [31] . We suggest because (1) the patients' CSF findings were compatible with that while results of further studies are pending, amphotericin meningitis from the time of the first lumbar puncture, (2) other B plus flucytosine remains the initial treatment of choice for pathogens were excluded, and (3) they responded to antifungal candidal meningitis. In our experience, the rate of survival treatment.
found with this regimen was 70%, a figure very similar to that Most patients in this study had symptoms for ú4 weeks noted in recent series in which amphotericin B and fluconazole before admission, suggesting that a subacute or chronic course were available [25, 28] . is also the usual form of presentation of candidal meningitis One study reported that a prolonged course before diagnosis; in HIV-infected patients. Mild lymphocytic or polymorphonuhypoglycorrachia; and the presence of intracranial hypertension clear pleocytosis, a raised protein level, and hypoglycorrachia or focal neurological deficits were risk factors for increased were the predominant CSF findings, abnormalities indistinmortality in cases of candidal meningitis [22] . Because of the guishable from those noted with tuberculous, cryptococcal, and low number of cases reported and the variability in CD4 cell even bacterial meningitis, which occur more frequently in HIVcounts, we could not assess any prognostic factor among HIVinfected patients [7, 8] .
infected patients with candidal meningitis. Empirical tuberculous treatment was started for 50% of paCharacteristically, maintenance antifungal treatment was tients before a definitive diagnosis, and even in three patients given to 63% of the patients. Although the rate of relapse in this the adenosine deaminase activity value was ú10 IU/L, a cutoff population is unknown, suppressive treatment with fluconazole with high specificity for the diagnosis of tuberculous meningitis was used in our five cases, despite clinical and mycologic [24] . Therefore, definitive diagnosis of candidal meningitis response, because of the persistence of CSF abnormalities and subjacent immunodepression. The patient who stopped taking needs to be documented by culture; culture of a large volume / 9c37$$se01 08-19-97 13:17:18 cida UC: CID
